Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).
about
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.Specific organ metastases and survival in metastatic non-small-cell lung cancer.Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets.Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients.Management of elderly patients with advanced non-small cell lung cancer: a single-center experience.
P2860
Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Prognostic factors for respons ...... all cell lung cancer. (NSCLC).
@en
type
label
Prognostic factors for respons ...... all cell lung cancer. (NSCLC).
@en
prefLabel
Prognostic factors for respons ...... all cell lung cancer. (NSCLC).
@en
P2093
P1433
P1476
Prognostic factors for respons ...... all cell lung cancer. (NSCLC).
@en
P2093
Berchier MC
Klastersky J
Paesmans M
P356
10.1016/S0169-5002(96)00609-5
P577
1996-12-01T00:00:00Z